SCHEMBL23499863

SCHEMBL23499863

CC(=O)c1ccc(-c2ccc(C(F)(F)F)nc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.50
KCNH2 Q12809 4/20 0.48
MAP4K4 O95819 1/20 0.48
PIK3CA P42336 1/20 0.48
MINK1 Q8N4C8 1/20 0.48
PI4KB Q9UBF8 1/20 0.48
SYK P43405 1/20 0.47
HSD17B1 P14061 1/20 0.47
MAPT P10636 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
PDE10A Q9Y233 1/20 0.46
MCHR1 Q99705 1/20 0.43
TRPV4 Q9HBA0 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29456932 0.86 TRPV4 (0.48) KIF11KCNH2SYKMAPTSMN1; SMN2
SCHEMBL934659 0.86 TRPV4 (0.48) KIF11KCNH2SYKMAPTSMN1; SMN2
SCHEMBL2340910 0.85 RXRA (0.53) MAP4K4
Hydrochloric Acid SCHEMBL4727672 0.83 TRPV4 (0.46) KIF11KCNH2SYKMAPTSMN1; SMN2
SCHEMBL2340659 0.83 CA12 (0.53) KCNH2MAP4K4PIK3CAMINK1PI4KB
SCHEMBL483725 0.77 HSD17B1 (0.52) KIF11HSD17B1MAPTSMN1; SMN2MCHR1
SCHEMBL30536021 0.77 KIF11 (0.52) KIF11KCNH2MAP4K4PIK3CAMINK1
SCHEMBL322603 0.77 KIF11 (0.52) KIF11KCNH2MAP4K4PIK3CAMINK1
SCHEMBL23500079 0.75 MAPT (0.53) KIF11HSD17B1MAPTSMN1; SMN2
SCHEMBL1138580 0.75 HSD17B1 (0.53) HSD17B1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12486246-B2 Replication protein A (RPA)-DNA interaction inhibitors THE TRUSTEES OF INDIANA UNIVERSITY (US) 2025-12-02 US disclosed
US-20230056729-A1 REPLICATION PROTEIN A (RPA)-DNA INTERACTION INHIBITORS NATIONAL INSTITUTES OF HEALTH 2023-02-23 US disclosed
EP-4073055-A1 REPLICATION PROTEIN A (RPA)-DNA INTERACTION INHIBITORS The Trustees of Indiana University (US) 2022-10-19 EP disclosed
WO-2021119242-A1 REPLICATION PROTEIN A (RPA)-DNA INTERACTION INHIBITORS THE TRUSTEES OF INDIANA UNIVERSITY (US) 2021-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12486246-B2 Replication protein A (RPA)-DNA interaction inhibitors RPA1, RPA3, RPAP1 KIF11 3339/4885KCNH2 4856/4885MAP4K4 1539/4885
US-20230056729-A1 REPLICATION PROTEIN A (RPA)-DNA INTERACTION INHIBITORS RPA1, RPA3, RPAP1 KIF11 3339/4885KCNH2 4856/4885MAP4K4 1539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.